U.S. Markets closed

Immuron Limited (IMC.AX)


ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.22+0.01 (+4.76%)
At close: 2:55PM AEST

Immuron Limited

Unit 10
25–37 Chapman Street
Blackburn North, VIC 3130
Australia
61 3 8892 4854
http://www.immuron.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedAge
Mr. Thomas LiquardChief Exec. Officer287.49kN/A45
Mr. Peter AnastasiouExec. Vice Chairman40kN/A37
Dr. Jerry Kanellos Ph.D.Chief Operating & Scientific Officer163.97kN/A56
Mr. Phillip Allen Hains BBus(Acc), MBA, CAJoint CFO & Company Sec.N/AN/A58
Mr. Peter Vaughan BBus(Acc), CAJoint CFO & Company Sec.N/AN/A34
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle. The company markets and sells Travelan for the prevention of travellers’ diarrhea. Its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. The company also has other preclinical immunotherapy pipeline products targeting immune-related diseases. Immuron Limited has a research and development collaboration agreement with the Walter Reed Army Institute of Research (WRAIR) for the development of a Shigella vaccine; and Naval Medical Research Center for the testing of Travelan in cell lines of campylobacter and enterotoxigenic escherichia coli. The company was founded in 1994 and is based in Blackburn North, Australia.

Corporate Governance

Immuron Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.